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identification as outlined in a draft consensus paper at an 
expert meeting hosted by the German Federal Institute for 
Risk Assessment (BfR) in Berlin, Germany on 11–12 April 
2016. Participants reached a consensus regarding scientific 
principles for the identification of EDs. The paper discusses 
the consensus reached on background, definition of an ED 
and related concepts, sources of uncertainty, scientific prin-
ciples important for ED identification, and research needs. 
It highlights the difficulty in retrospectively reconstructing 
ED exposure, insufficient range of validated test systems 
for EDs, and some issues impacting on the evaluation of the 
risk from EDs, such as non-monotonic dose–response and 
thresholds, modes of action, and exposure assessment. This 
report provides the consensus statement on EDs agreed 
among all participating scientists. The meeting facilitated 
a productive debate and reduced a number of differences in 
views. It is expected that the consensus reached will serve 
as an important basis for the development of regulatory ED 
criteria.
Abstract Endocrine disruption is a specific form of toxic-
ity, where natural and/or anthropogenic chemicals, known 
as “endocrine disruptors” (EDs), trigger adverse health 
effects by disrupting the endogenous hormone system. 
There is need to harmonize guidance on the regulation of 
EDs, but this has been hampered by what appeared as a 
lack of consensus among scientists. This publication pro-
vides summary information about a consensus reached by a 
group of world-leading scientists that can serve as the basis 
for the development of ED criteria in relevant EU legisla-
tion. Twenty-three international scientists from different 
disciplines discussed principles and open questions on ED 
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Introduction
In summer 2013, when an initial draft of criteria for the 
identification of endocrine disrupters (EDs) was discussed 
within the European Commission (the executive of the 
European Union), a group of toxicology journal editors 
published severe scientific concerns about the proposed 
approaches (Dietrich et al. 2013). As a result, a controversy 
about the toxicological principles that should guide the 
identification of endocrine-disrupting chemicals flared up 
in the scientific press among toxicologists and endocrinolo-
gists (Bergman et al. 2013; Zoeller et al. 2014; Autrup et al. 
2015). The realization that this dispute had contributed to a 
degree of misunderstanding among decision-makers in the 
European Commission motivated a group of those involved 
in the debates to explore whether it might be possible to 
bridge the differing views and come to a common under-
standing. In this brief communication, we describe the 
political and regulatory context that has led to this debate, 
and present the consensus that has been reached among sci-
entists who took opposing views in the previous dispute, 
during a two-day workshop held in Berlin, Germany, 11–12 
April 2016, hosted by the German Federal Institute for 
Risk Assessment (BfR).
In line with established practice in other jurisdictions, 
the risk management of chemicals in the EU is generally 
based on risk characterization. However, for some toxico-
logical effects, the EU has introduced hazard-based regu-
lations. This applies especially to chemicals used as active 
substances in plant protection products and biocidal prod-
ucts. According to provisions in several pieces of EU law 
for plant protection products and biocidal products, the 
European Commission was obliged to develop scientific 
criteria for the identification of EDs by 2013, but to date 
(April 2016), has failed to do so.
Motivated by concerns about health effects caused by 
the delay in developing criteria for endocrine-disrupting 
substances, Sweden (a member state of the EU) brought 
a court case against the European Commission in 2014. 
Finally, in winter 2015, the General Court of the EU ruled 
that the Commission had breached EU law, by failing to 
adopt measures concerning the specification of scientific 
criteria for the identification of endocrine-disrupting sub-
stances. The Court further noted that the Commission’s 
defense that the scientific criteria which it had proposed 
were the subject of criticism, in summer 2013, was irrel-
evant to the fact that the Commission had an obligation to 
present these criteria according to the deadlines enshrined 
in EU law (December 2013) (General Court of the EU 
2015).
The apparent controversy among scientists centered 
on disagreements about the most appropriate approach 
to assess endocrine disruptors, and was focused on the 
scientific assumptions that could be made during the iden-
tification of a chemical as an endocrine disruptor. Promi-
nent in these disputes was the question of the existence of 
thresholds for endocrine disruptors and of the significance 
of non-monotonic dose–response relationships, which has 
a significant impact on the way risk assessments are con-
ducted for these chemicals (Dietrich et al. 2013; Bergman 
et al. 2013).
However, at the Berlin workshop, the protagonists of the 
scientific controversy were able to agree that the require-
ment for scientific criteria for the identification of endo-
crine disruptors per se, can be interpreted as an issue of 
hazard identification. This enabled the workshop partici-
pants to conclude that differences in opinion regarding the 
existence of thresholds and non-monotonic dose–response 
curves, although relevant to the risk characterization of 
EDs, are not a hindrance for defining scientific criteria for 
their identification. The consensus that was reached on sci-
entific principles for the identification of endocrine-disrupt-
ing chemicals is offered as advice to the European Com-
mission for the first step in their decision-making process 
to meet their legal obligations.
Consensus statement
Background
1. Key pieces of EU chemicals regulation, includ-
ing the Plant Protection Product Regulation (EU No 
1107/2009), the Biocidal Product Regulation (EU No 
528/2012), the Water Framework Directive (2000/60/
EC), REACH (EU No 1907/2006) and the Cosmetics 
Regulation (2009/1223/EC) include the aim of protect-
ing human health and the environment from exposures 
to endocrine disruptors.
2. The European Commission (EC) is engaged in a pro-
cess of elaborating specific scientific criteria for the 
identification of endocrine disruptors applicable to 
plant protection products and biocidal products. These 
criteria may have an impact on other pieces of EU leg-
islation dealing with chemicals.
3. There are past and ongoing differences among scien-
tists about the endocrinological, pharmacological and 
toxicological principles that should underpin scientific 
criteria for the identification of endocrine disruptors.
4. This paper represents an effort to establish a consensus 
among scientists who have taken part in these discus-
sions. The initiative for this attempt came from a small 
group of scientists actively engaged in endocrine dis-
ruptor research. We map out an agreement about sci-
entific principles that can underpin the identification 
of endocrine disruptors in the European Union (EU) 
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according to the principle “One Substance—One Toxi-
cological Assessment”.
5. The absence of accepted criteria for the identification 
of endocrine disruptors presents a significant stumbling 
block for a scientifically based regulation of endocrine 
disruptors that is enshrined in key pieces of EU chemi-
cals regulation.
6. We acknowledge that there is a need in the EU to 
ensure continuation and enhancement of policies for 
the protection of human health and the environment 
from the effects of endocrine disruptors and those sci-
entifically based criteria for the identification of endo-
crine disruptors are necessary for regulatory decision-
making processes.
7. We recognize that the European Parliament, in its res-
olution of 14 March 2013 on the protection of public 
health from endocrine disruptors (P7_TA (2013)0091), 
took the view that these criteria should conform to the 
WHO/IPCS definition of endocrine disruptors, and 
should be based on the best available science.
8. The field of “endocrine disruptor research” draws from 
many scientific disciplines including physical chemis-
try, biochemistry, molecular biology, toxicology, phar-
macology, endocrinology, developmental biology, epi-
demiology, clinical medicine and many others. Each of 
these fields can have a different language and a differ-
ent logic to understand the unique complexities of their 
particular level of investigation.
9. We recognize that the views of scientists working 
at different levels of investigation and with different 
training and research experience may contribute to the 
appearance of a debate when the topic cuts across mul-
tiple disciplines. Therefore, we believe the most impor-
tant consensus that we can achieve is one that relates 
to the principles, which should form the basis of the 
development of scientific criteria for the identification 
of endocrine disruptors [as requested by EU legisla-
tion].
Definition of endocrine disruptors and related concepts
10. We acknowledge the WHO definition of an endo-
crine disruptor as follows: “An ED is an exogenous 
substance or mixture that alters the function(s) of the 
endocrine system and consequently causes adverse 
effects in an intact organism, or its progeny, or (sub) 
populations”.
 (a) Alterations of the function of the endocrine 
system may arise from interaction with hor-
mone receptors, changes in circulating lev-
els of the hormone, and from the impact of 
chemical(s) on hormone synthesis, transport, 
metabolism and other factors.
(b) In the WHO definition, the term “adverse effect” 
refers to “A change in morphology, physiology, 
growth, reproduction, development or lifespan 
of an organism which results in impairment of 
functional capacity or impairment of capacity to 
compensate for additional stress or increased sus-
ceptibility to the harmful effects of other environ-
mental influences”.
(c) The term “intact organism” is understood to mean 
that the effect would occur in vivo, either observ-
able in a test animal system, epidemiologically or 
clinically. However, it does not necessarily mean 
that the adverse effect has to be demonstrated in 
an intact test animal, but may be shown in ade-
quately validated alternative test systems predic-
tive of adverse effects in humans and/or wildlife. 
The importance of mechanistic data derived from 
experimental systems (in vitro or in vivo in which 
the animals have been surgically or genetically 
altered as part of a focused experiment) was also 
recognized.
11. We acknowledge that certain hormones interact with 
their receptors according to an equilibrium reaction. 
Accordingly, the concentrations of both free hormone 
and free receptor are important variables controlling 
hormone action, explaining why different cells and tis-
sues at different times during development are differ-
entially sensitive to the hormone.
12. Experimental work has led to a better understanding 
of the role of hormones in development and during the 
maintenance of physiological functions. We recognize 
that disruption of the programming role of hormones 
during prenatal and postnatal development can cause 
adverse effects that do not become evident until later in 
life.
13. Interference with the role of many hormones during 
the maintenance of physiological functions in adult life 
can also lead to adverse effects.
14. We resolve that the scientific knowledge about the 
principles that govern the induction of adverse effects 
by disrupting the programming function of hormones 
during development is sufficiently advanced to warrant 
regulatory action.
Sources of uncertainty
15. We recognize that the identification of chemicals that 
contribute to adverse effects on human health is fraught 
with difficulties which, in the case of endocrine disrup-
tors, can be traced to several specific factors. Many of 
the critical events discussed in the context of endocrine 
disruption in humans may occur in fetal life, during 
childhood or puberty. Exposures during these periods 
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are often difficult to reconstruct, thus obscuring any 
causal relationships that may exist. Some chemicals 
whose health effects have been relatively well studied 
in other areas, have also been subjected to the assess-
ment of endocrine effects, but other chemicals in wide-
spread commercial use have not been evaluated so.
16. On the other hand, the existing framework of interna-
tionally validated test systems for the identification 
of endocrine disruptors must be further developed to 
ensure detection of health effects relevant to endo-
crine disruption in humans. For example, test systems 
suitable for the identification of effects consequent to 
many specific modes of action in disrupting the func-
tion of hormone systems are missing, although efforts 
to address these gaps are ongoing.
17. Non-monotonic dose–response relationships and 
low-dose effects of endocrine disruptors have been 
described in the literature. The implications of these 
observations for testing strategies and risk assess-
ment continue to be debated, and we acknowledge the 
importance of this scientific discourse. However, we 
believe that a consensus about these issues is unlikely 
to emerge in the near future. Nevertheless, in our view 
the establishment of criteria for the identification of 
endocrine disruptors is possible without resolution of 
these issues.
18. We emphasize that these sources of uncertainty should 
not delay current efforts to regulate endocrine disrup-
tors. Nevertheless, elucidation of the above issues 
which are significant sources of uncertainty will 
require considerable research efforts in the future. 
These efforts will be essential for scientifically based 
regulations of endocrine disruptors in key pieces of EU 
chemicals regulation.
Scientific foundations of regulatory decision‑making
19. The various relevant pieces of EU chemicals regulation 
require both hazard and risk assessment approaches1 to 
enable decision-making to be applied in different ways.
20. The identification of a compound as an endocrine dis-
ruptor is a hazard identification procedure. Established 
principles governing disruption of the programming 
function of hormones mean that hazard identification 
for endocrine disruption has to take account of the tim-
ing of exposure relative to life stage and that transient 
indices or effects should not necessarily be considered 
adverse.
1 The WHO IPCS definitions for the four steps in risk assessment: 
hazard identification, hazard characterization, exposure assessment 
and risk characterization, have been used throughout this document.
21. We recognize that certain adverse outcomes appear-
ing to arise from endocrine disruption can also occur 
through non-endocrine modes of action. Moreover, 
adverse effects or modes of action consistent with 
endocrine-disrupting characteristics but demonstrated 
to be non-specific effects secondary to another toxic 
effect are not considered appropriate for identification 
of endocrine disruption. The identification of a chemi-
cal as an endocrine disruptor therefore has to rely on 
weight-of-evidence evaluations of both adversity and 
mode of action together. We agree that endocrine activ-
ity on its own should not trigger a chemical’s identifi-
cation as an endocrine disruptor.
22. We agree that a chemical’s potency to induce an 
adverse effect is an important factor for consideration 
during the characterization of the hazards of endocrine 
disruptors. However, potency is not relevant for iden-
tification of a compound as an endocrine disruptor. 
However, there may be high doses (e.g. the oral toxic-
ity limit of 1000 mg/kg body weight/day) above which 
identification as an ED would not be warranted.
23. Criteria for identifying chemicals as endocrine disrup-
tors would need to be accompanied by the implementa-
tion of relevant test systems in EU regulations. We note 
that many relevant OECD guidelines exist which have 
not yet been consistently integrated into the regulatory 
frameworks. There is lack of validated tests for a num-
ber of modes of actions. We recommend that respective 
EU directives, regulations and other relevant guidance 
are updated to incorporate validated and internation-
ally agreed test systems for endocrine disruptors. In 
this context, guidance and scientific advice need to 
be updated to indicate how the outcome of those tests 
should be evaluated in the regulatory context, and to 
include endocrine pathways and adverse health effects 
that are insufficiently explored by current toxicological 
testing.
24. This document has focused on the identification of 
endocrine disruptors. However, the assessment of the 
corresponding risks on human health and wildlife 
would further require consideration of dose–response 
relationships, including potency, exposure assessment 
and risk characterization, including susceptible sub-
populations, severity and reversibility of effects. This 
emphasizes the importance of the “One Substance—
One Toxicological Assessment” philosophy, and has 
implications for data generation of both regulated and 
unregulated chemicals.
Research needs
25. More effective regulation could be achieved by clos-
ing certain knowledge gaps. We recommend that these 
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knowledge gaps should be identified through a system-
atic gap analysis. Notwithstanding such an analysis, we 
recognize that future research needs to include the fol-
lowing main areas:
(a) Exposure assessment of EDs,
(b) Epidemiological studies of EDs with accurate 
characterization of exposures during relevant time 
periods,
(c) Experimental research to clarify ED modes- and 
mechanisms-of-action, to produce an improved 
understanding of the molecular events underly-
ing adverse outcomes and to better understand 
whether irreversible effects of developmental pro-
gramming are induced in a threshold-dependent 
manner or not, and
(d) Test method and biomarker development, includ-
ing validation, to ensure more sensitive and robust 
identification of EDs.
26. We recognize that exposure assessments based on 
effect measurements and/or on a wide range of chemi-
cals have the potential to identify previously unrecog-
nized endocrine disruptors.
27. Resolution of the issues of non-monotonic dose–
response relationships and whether effects are thresh-
old-dependent requires systematic efforts to understand 
the mechanisms underlying adverse effects of endo-
crine disruptors.
28. The existence of dose-thresholds for endocrine disrup-
tors continues to be debated. We recognize that it may 
be difficult to distinguish a true threshold from an appar-
ent threshold which merely arises from the limits of 
detection of the experimental system. Thus, the question 
of the existence of dose-thresholds for endocrine disrup-
tors cannot be resolved through empirical dose–response 
studies alone, but has to rely on mechanistic investiga-
tions and increased knowledge on the functions and 
programming of the endocrine system during specific 
windows of sensitivity. Such research is not considered 
a prerequisite for the identification of endocrine disrup-
tors, but it is necessary for their risk assessment.
29. Many assays, models and tools for the study of ED-
related modes and mechanisms of action already exist, 
but have not been taken forward into the assay valida-
tion process. A systematic analysis is needed to estab-
lish which existing assays are ready for validation.
30. While many existing “scientific tools” could be refined 
into validated assays, suitable model systems and assays 
are missing for certain mechanistic aspects of endocrine 
disruption. Concerted research and development efforts 
are needed to fill these gaps and are being developed.
31. The Commission requires that animal testing should 
be reduced and avoided where possible. Hence, there 
is a need to develop approaches that can reliably detect 
endocrine-disrupting chemicals using non-animal 
methods, with at least the same reliability as current 
methods. Criteria will be necessary to determine the 
acceptability of such methods.
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Glossary
Chemicals   Natural and anthropogenic 
substances as defined by their 
chemical structures.
Chemicals legislation  Substance and product-based 
legislation aiming at minimizing 
environmental and health risks 
currently relevant to endocrine 
disruption such as plant protec-
tion products (EC 1107/2009), 
biocides (EU 528/2012), food 
additives (EC 1333/2008), 
REACH (EC 1907/2006), food 
contact materials (EU 10/2011), 
cosmetics (EC 1223/2009).
Endocrine disruptor  WHO definition: An endocrine 
disruptor is an exogenous sub-
stance or mixture that alters 
function(s) of the endocrine 
system and consequently causes 
adverse health effects in an 
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intact organism, or its progeny, 
or (sub)populations.
Hazard identification  IPCS definition: The identifica-
tion of the type and nature of 
adverse effects that an agent has 
an inherent capacity to cause in 
an organism, system or (sub)-
population. Hazard identifica-
tion is the first stage in hazard 
assessment and the first step in 
the process of risk assessment.
Hazard characterization  IPCS definition: The qualita-
tive and, wherever possible, 
quantitative description of the 
inherent properties of an agent 
or situation having the potential 
to cause adverse effects. This 
should, where possible, include 
a dose–response assessment 
and its attendant uncertainties. 
Hazard characterization is the 
second stage in the process of 
hazard assessment and the sec-
ond step in risk assessment.
One Substance One—  A chemical that falls under several
Toxicological      regulatory systems would have
Assessment    only one assessment, which 
would be accepted by all of the 
regulatory systems. This does 
not necessarily imply that the 
regulatory decision would be 
the same, which would depend 
on a number of considerations.
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